Neural Implant Interface Engineering Patent Landscape 2026
- Filings peaked in 2020 at 22 and have since fallen back toward 2017 levels, with 2026 filings (partial) matching the 2017 starting point of 2 — the claim rush around electrode-tissue interface language has already happened.
- A61N carries every record in this set while A61B and A61F each sit under 15, showing that electrotherapy-classified claims are the anchor and diagnosis/prosthetic crossover filings remain a minority.
- The US receives 26 filings against 17 at the EPO and 14 via WIPO, so a filing strategy built only around US and EP coverage will miss PCT-routed applicants still choosing their national phase.
Top-5 share is the combined record count of the five largest assignees divided by all 75 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This set tracks patent families that combine neural implant, neural interface or brain-computer interface language in the title/abstract with specific electrode-tissue interface terms — electrode-tissue interface, neural electrode coating, charge injection, or biotic-abiotic interface — inside the claims or description, filtered to the A61N1/05, A61B5/24 and A61N1/36 IPC classes. That combination isolates the engineering layer that sits between a device and living tissue, rather than the broader universe of implant or signal-processing patents.
Seventy-five records span 2015 through the 2026 cut-off. Because publication lags filing by roughly eighteen months, the last one to two years of the trend will always look thinner than they eventually turn out to be once later filings publish.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 75-family set: how filing volume has moved year over year, and which IPC subclasses the claims actually sit in.
Filings rose to a 2020 peak, then declined
From 2 filings in 2017, activity climbed to 22 in 2020, cooled to 7 at the 2022 midpoint, and 2026 (partial) sits back at 2. The shape reads as a concentrated filing wave rather than a steadily building field, though the final 2025–2026 count will rise as later publications land.
A61N dominates; supporting classes are thin
Every one of the 75 records classifies under A61N (electrotherapy & radiation therapy), with A61B (diagnosis & surgery, 13) and A61F (implants & prostheses, 11) as the next-largest groups. Materials- and optics-adjacent classes — B29C, G02B, B29K, B29L, G06F — each carry four or fewer records, indicating that fabrication-method and optical-interface claims are still a small fraction of this corpus.
Shares are the percentage of the 75 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Neural Implant Interface Engineering with Eureka
This page is one run against one query. Ask Eureka your own question about neural implant interface engineering and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited records
Neural interface fiber (US20260000332A1)
The filing describes a fiber-form neural interface: a bundle of conductive structures wrapped in a dielectric cladding, with openings in the cladding exposing portions of individual conductors so they contact tissue at defined points along the fiber, plus an end cap that insulates the conductor bundle at the distal tip.Abstract trimmed for length; see the full record for complete claim language.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20080208283A1 | Neural Interface System | 91 |
| 2 | US20130237906A1 | Liquid crystal polymer-based electro-optrode neural interface, and method for producing same | 67 |
| 3 | WO2008109298A2 | Neural interface system | 62 |
| 4 | US20090024182A1 | IrOx Nanostructure Electrode Neural Interface Optical Device | 27 |
| 5 | US9604051B2 | Neural interface system | 18 |
| 6 | US20140296951A1 | Neural Interface System | 16 |
| 7 | WO2021108810A1 | Electrode devices for neuromodulation and related methods | 14 |
| 8 | JP2013543743A | 液晶ポリマー基盤のエレクトロオプトロード神経インターフェース及びその製造方法 | 9 |
| 9 | US20200306534A1 | Neural interface device for stimulation of a nerve and measuring impedance | 8 |
| 10 | US20210093868A1 | Bipoloar and tripolar confirguration for unidirectional stimulation of a-type nerve fibers | 8 |
Citation counts favour older records simply because they have had longer to accumulate them — read this as a map of influence on later filings, not a ranking of current importance.
Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three read-throughs from the trend, classification and citation data — useful for deciding where a new filing is likely to face dense prior art versus open ground.
The wave has already crested
A field that climbed from 2 filings in 2017 to 22 in 2020 and has since fallen back toward its starting rate looks like a completed land-grab around electrode-tissue interface claim language, not an emerging one. New entrants should expect the core coating and charge-injection claim space to already be occupied by the 2019–2021 cohort.
Electrotherapy claims anchor the set
Every record in this corpus sits in A61N, confirming the search is correctly centred on stimulation/electrode hardware rather than passive sensing. The smaller A61B and A61F counts mark the diagnosis and prosthetic-integration angles as secondary, not absent — worth checking individually before assuming full coverage.
Citation leaders are early, not current
The most-cited records in this set are the older "neural interface system" families, cited 91, 67, 62 and 27 times. High citation counts here mark foundational claim language that later filers had to design around, not technology still being actively extended today.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to neural implant interface engineering, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Galvani Bioelectronics Ltd. | THE TRUSTEES OF INDIANA UNIV | 3 |
| University of Southern California | California Institute of Technology | 3 |
| University of Southern California | The Regents of the University of California | 3 |
| California Institute of Technology | The Regents of the University of California | 3 |
| Galvani Bioelectronics Ltd. | ZAIDI FAISAL | 2 |
| Galvani Bioelectronics Ltd. | GALVANI BIOELECTRONICS INC | 2 |
| NEURAL DYNAMICS TECHNOLOGIES INC | VAN WELIE INGRID | 2 |
| NEURAL DYNAMICS TECHNOLOGIES INC | SCHOLVIN JORG | 2 |
Nine co-assignee pairs appear in the set, each tied to three joint records — university-industry pairings (e.g. a bioelectronics company filing jointly with a university trustee board) and university-university pairings appear at the same strength, suggesting collaborative filing is occasional rather than a dominant pattern here.
Who holds the claim space
Assignee momentum in this set has gone quiet: every tracked assignee, including Precision Neuroscience Corp, shows zero families in the latest year, with Precision Neuroscience's count down 100% year over year. That flatline is consistent with the post-2020 filing decline rather than any single company's retreat.
Recent-cohort filer, now quiet
Precision Neuroscience Corp appears among the named assignees with a full year-over-year drop to zero filings, matching the broader cooling in this set rather than signalling an isolated pullback.
University-industry pairing is the strongest link
The bioelectronics company and a university trustee board form one of three co-assignee pairs tied at three shared families each, alongside two university-only pairings of the same strength — evidence of steady but not dominant joint filing.
US-first, PCT close behind
The United States receives the largest share of filings, but the EPO and WIPO/PCT routes combined exceed it, so an assignee-tracking strategy limited to US publications will miss a large share of this field's activity.
| Assignee | Recent year | YoY |
|---|---|---|
| Galvani Bioelectronics Ltd. | 0 | — |
| The Board of Trustees of the Leland Stanford Junior University | 0 | — |
| MI Tech Co., Ltd. | 0 | — |
| PRECISION NEUROSCIENCE CORP | 0 | -100% |
| Medtronic Bakken Research Center B.V. | 0 | — |
| University of Southern California | 0 | — |
| California Institute of Technology | 0 | — |
| The Regents of the University of California | 0 | — |
Where to take this
Two directions follow directly from the data above: checking freedom-to-operate against the densest claim clusters, and scanning the thinner IPC branches for open filing room.
Run a freedom-to-operate check on the 2019–2021 cohort
The filing peak sits in 2020; any new coating or charge-injection claim should be checked against that cohort specifically, since it holds the densest concentration of electrode-tissue interface language in the set.
Explore prior art with Eureka →Map the thin IPC branches before drafting
B29C, G02B, B29K, B29L and G06F each carry four or fewer records — worth a closer look before assuming those fabrication and optics angles are already claimed.
Map white space with Eureka →Common questions on this landscape
This dataset pulls records whose title or abstract references a neural implant, neural interface or brain-computer interface, and whose claims or description use terms like electrode-tissue interface, neural electrode coating, charge injection, or biotic-abiotic interface, restricted to the A61N1/05, A61B5/24 and A61N1/36 IPC classes. That means a general implant patent without coating- or interface-specific language would not appear here, even if it covers a neural device. The scope is intentionally narrow to isolate the tissue-contact engineering layer rather than the whole implant.
The trend in this set shows growth from 2 filings in 2017 to a peak of 22 in 2020, then a fall to 7 by 2022 and down to 2 by 2026. That shape is consistent with an initial wave of claim-staking around coating and charge-injection language that has largely run its course, rather than a market that is shrinking. It is worth remembering publication lag: filings from the last 18 months are undercounted in any live dataset, so the true 2024-2026 picture is likely higher than shown today.
The United States receives the most filings in this set at 26, but Europe (EPO) and the WIPO/PCT route together account for more filings than the US alone, at 17 and 14 respectively. A monitoring program limited to USPTO publications will therefore miss a meaningful share of this field's activity, particularly PCT applications that have not yet entered national phase. Tracking all three routes gives a fuller picture of where competitors are seeking protection.
Not on their own. The most-cited records in this set — reaching as high as 91 citations — are largely the earlier "neural interface system" filings, which have simply had more time in the corpus to accumulate citations. High citation counts mark foundational claim language that later filers had to work around, but they do not indicate which technical approaches are being actively pursued now. Pair citation data with the filing-trend and assignee-momentum figures before drawing conclusions about current relevance.
The IPC composition points to several thin branches: B29C (plastics shaping), G02B (optical elements), B29K/B29L (plastics materials and products) and G06F (digital data processing) each carry four or fewer of the 75 records, against 75 for A61N. That suggests fabrication-method claims around coating processes, optical electro-optrode integration, and software/electrode co-claims are comparatively under-claimed. Any filing strategy targeting these branches should still run a freedom-to-operate check against the dominant A61N cluster, since device-level claims there may still read on a new fabrication or optical approach.
Research Neural Implant Interface Engineering in depth with Eureka
Go past this page: query the whole neural implant interface engineering corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.